A Pharmacogenomic Basis for Tolerance of 5-Fluorouracil Following Early, Severe Toxicity from Capecitabine in a CDA Ultrarapid Metabolizer Colon Cancer Patient: A Case Report
This case shows that the severe adverse effects of capecitabine therapy in a patient with a CDA ultrametabolizer profile can be successfully switched to 5-FU-based therapy at a normal dose and tolerate this alternative fluoropyrimidine.
Authors
- Tinashe Mazhindu (ORCID: https://orcid.org/0000-0003-3446-3049)
- Zedias Chikwambi (ORCID: https://orcid.org/0000-0002-8638-6236)
- Margaret Borok (ORCID: https://orcid.org/0000-0002-1234-0913)
- Ntokozo Ndlovu (ORCID: https://orcid.org/0000-0002-8269-7571)
- Edith Matsikidze (ORCID: https://orcid.org/0009-0009-1731-6136)
- Collen Masimirembwa (ORCID: https://orcid.org/0000-0001-5951-5525)
- Kevin Grimes
Institutions
- University of Zimbabwe (ZW)
- African Institute of Biomedical Science and Technology (ZW)
- Stanford University (US)
Publication Details
- Journal
- Cancer Management and Research
- Published
- 2026-02-01
- DOI
- https://doi.org/10.2147/cmar.s571794
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- American Association for Cancer Research
- Bill and Melinda Gates Foundation